Methods of Identifying Novel Proteins and Antigens in Cancer Cells

Categories:  “Cancer Therapeutics,” “Diagnostics,” “Research Tools

Reference #: 2017-002

OTC Contact: Ruchika Nijhara Ph.D., MBA, Director (Directory Information | Send a Message)

Contracts Guide

Disclose Your Invention
MTA/CDA Assistance
COVID-19 Related Agreements
Main Campus Research
Office of Sponsored Research
Education Links

Connect with Industry

Technologies for Licensing
Industry Collaboration Opportunities
Research and Clinical Trials

Invention

Neoantigens are mainly tumor-specific antigens generated by mutations in tumor cells and are only expressed in tumor cells. Despite the increasing interest in clinical interventions targeting neoantigens, substantial challenges remain to enable a more precise identification of neoantigens that are relevant for patient treatment. Georgetown researchers have developed novel methods of identifying neoantigens or potential neoantigens. The method involves sequencing of isolated long-read messenger RNA (mRNA) through Single-Molecule Real-Time (SMRT) Full-Length RNA-Sequencing.

Background

Neoantigens have become compelling targets for cancer immunotherapy due to high levels of immunogenicity and have also been shown to be effective in immune checkpoint blockade therapy. Therefore, neoantigens may serve as predictive biomarkers and synergistic treatment targets in cancer immunotherapy. Neoantigen candidate selection and identification usually rely on the spectra of somatic mutations identified by whole-exome sequencing (WES) coupled with RNA-seq. This approach suffers from a lack of direct experimental evidence of the real presence of predicted epitopes on the cell surface. Georgetown researchers developed methods of identifying neopeptides in abnormal cells, by sequencing isolated long-read messenger RNA (mRNA) through Single-Molecule Real-Time (SMRT) Full-Length RNA-Sequencing.

Applications

Advantages

Stage of Development

Studies are being conducted to analyze melanoma samples by SMRT.

Patent Status

PCT/US17/045057 Methods for Identifying Novel Proteins and Antigens in Cancer Cells

Inventor

Anton Wellstein